Macro Dashboard
| Indicator | Level | 5-Day Change | Signal |
|---|---|---|---|
| KOSPI | 5,060 | −13.6% | Bear |
| KOSDAQ | 644 | −12.3% | Bear |
| USD/KRW | 1,356 | +2.3% | KRW weak |
| VIX | 26.8 | +26.6% | Caution |
| Brent | $98.4 | −6.1% | Falling |
| US 10Y | 4.84% | −0.09pp | Stable |
Korea regime: Bear. US regime: Neutral — the US just downgraded from Bull this run. Only 14.5% of Korean stocks trade above their 50-day moving average; 12.8% above the 200-day. KOSPI sits at 5,060 against a 200DMA of 6,511. KRX program selling hit −₩1.61 trillion on the session, basis −0.28.
Market Wrap
Source: KR Market Snapshot, 2026-11-06. No same-day close briefing was available; a stale prior briefing was intentionally blocked.
Today’s session was a broad, largely indiscriminate selloff. Of 2,595 stocks tracked, 2,035 declined and only 335 advanced — an advance-decline ratio of roughly 1:6. The average stock fell 2.34%. Program selling (−₩1.61 trillion net, nearly all non-arbitrage) confirmed systematic de-risking rather than targeted rotation. ETF net creation was a modest +₩181 billion — passive inflows providing a marginal cushion against the tide.
Batteries and semiconductors led the decline. Samsung SDI (006400.KS, −8.06%), LG Chem (051910.KS, −5.69%), EcoPro (086520.KS, −6.89%), and L&F (066970.KQ, −12.60%) all fell sharply, with institutions actively selling SDI and L&F. On the semiconductor side, TES (095610.KS, −11.59%), Dooson Tesna (131970.KS, −10.85%), FADU (440110.KQ, −10.27%), and TCK (064760.KQ, −11.41%) were battered. Korea Finance Holdings (071050.KS, −17.34%) stood out as the worst single-name move, with heavy institutional selling.
Internet and IT services were the clearest defensive pocket. NAVER (035420.KS, +2.87%) was the only large-cap that attracted both foreign and institutional buying simultaneously. Samsung SDS (018260.KS, +6.34%) also drew institutional flows. Samsung Biologics (207940.KS, −0.26%) was nearly flat — the healthiest of the defensives among large caps.
Foreign flow diverged from price. Foreigners sold financials outright: KB Financial (105560.KS, −3.82%), Woori Financial (316140.KS, −1.72%), and Shinhan (055550.KS, −2.25%) all saw foreign outflows. Samsung C&T (028260.KS, −5.85%) and Samsung SDI were also on the foreign sell list. On the other side, foreigners bought POSCO Holdings (005490.KS, −3.11%) and TES despite price declines — a potential signal for recovery scenarios.
Institutions bought financials that foreigners sold. KB Financial, Woori, Shinhan, and Hyundai Motor (005380.KS) all appeared on institutional buy lists. The setup — foreign selling, domestic institutional absorbing — may reflect a rotation toward domestic yield plays as Korean 10-year bonds fell to 3.887%, a five-week low. Korean AA− corporate spreads over 3-year KTBs tightened to 0.69pp, one of the more stable readings in the current drawdown.
Today’s Quality Re-Rating Candidates
Source: KR Meta Screener, 2026-11-06. The PEAD-only screener intersection shows no 2+ overlaps today on that dimension; multi-signal analysis draws on the full meta screener combining 8 screener families across 104 tickers.
Today’s meta screener calibrates weights on 95 days of live forward returns. The dominant signal is consensus revision (2.18× weight, +1.76pp vs. pool average over 97 sample days). RS80 leadership (1.31×) and quiet accumulation (1.00×) follow. The financial-quality factor cluster — Quality Compounder, Smart Money Quality, Cycle Rerating, Smart Money Earnings — carries 0.60× per family, meaningful when stacked but not dominant alone.
Top Candidates — 2026-11-06
| Rank | Ticker | Name | Meta Score | Screener Families | Evidence Pts | Key Metrics |
|---|---|---|---|---|---|---|
| 1 | 011200.KS | HMM | 34.2 | Consensus Up, Quiet Accum., RS80 | 4 | Consensus z +0.52; retail −₩21.96B; RS80 pivot gap +10.5% |
| 2 | 128940.KS | Hanmi Pharm | 54.7 | Consensus Up, Cycle, SM Quality, SM Earnings | 5 | Margin +2.2pp; F+QI net +₩73.3B 5-day; DART catalyst |
| 3 | 086450.KS | Dongkook Pharma | 68.1 | Quality, Cycle, PEAD, Quiet Accum. | 5 | ROE 9.9%; OP YoY +20.1%; margin +0.5pp |
| 4 | 089590.KS | Jeju Air | 23.3 | Consensus Up | 3 | Consensus z +5.78; IR event catalyst; retail −₩10.65B |
| 5 | 071970.KS | HD Hyundai Marine Engine | 20.5 | Consensus Up | 3 | Consensus z +0.51; Q3 prelim + supply contract filed |
| 6 | 079160.KS | CJ CGV | 19.1 | Consensus Up | 2 | Consensus z +0.83; Q3 prelim filed today |
| 7 | 383800.KS | LX Holdings | 17.0 | Consensus Up | 2 | Consensus z +3.88; Q3 prelim filed Nov 4 |
Top 3 in Detail
#1 — HMM (011200.KS): Three Independent Signals, No DART Risk Flags
HMM is Korea’s largest container shipping line. It ranks first because it combines three independently weighted signal families: rising analyst consensus (z +0.52), quiet accumulation by foreigners and quality institutions while retail sold −₩21.96 billion, and RS80 leadership that cleared the late-stage filter (20-day flow/volume momentum +21.6%, box risk −14.7%). No filings appeared in the DART lookback window — the absence of risk disclosures is a clean read in the current environment. The RS80 weight (1.31×) stacked on consensus (2.18×) explains the top meta rank despite fewer quality-factor signals than the names below it. What to check next: spot freight rate trends and Q3 earnings timing.
#2 — Hanmi Pharm (128940.KS): DART Catalyst + Four Screeners + Smart Money vs. Retail Divergence
Hanmi Pharmaceutical is one of Korea’s leading biopharmaceutical companies, known for GLP-1, oncology, and rare disease pipelines. It hits four screener families: Cycle Rerating (operating margin expanded +2.2pp), Smart Money Quality (foreigners and quality institutions absorbed a net +₩73.3 billion over five days while retail sold −₩58.83 billion), Smart Money Earnings, and consensus revision. The DART overlay adds confirmed catalysts: a Fabry disease drug (LAGLA) licensing deal filed Oct 30, plus two IR events in late October and early November. The divergence between retail outflows and institutional/foreign inflows is the sharpest flow split in today’s candidate pool. What to check next: LAGLA deal geography and upfront payment structure; whether the IR calendar signals Q3 results disclosure.
#3 — Dongkook Pharma (086450.KS): Quality Compounder + Cycle + PEAD — Operational Leverage Stacking
Dongkook Pharmaceutical is a mid-cap consumer health and prescription drug company with a branded OTC portfolio alongside ethical pharmaceuticals. It clears four screener families: Quality Compounder (ROE 9.9%, OP YoY +20.1%), Cycle Rerating (margin +0.5pp), PEAD (OP YoY 20%, revenue +14.1%, 52-week gap remaining 21.2%), and quiet accumulation (retail −₩6.85 billion absorbed by foreigners and quality institutions). The raw meta score of 68.1 is the highest in today’s pool. It also appears independently in the PEAD Tier C list. The core story is operational leverage: revenue growth converting into margin expansion and beginning to attract institutional re-pricing. What to check next: OTC vs. prescription revenue mix and whether the OP growth rate is sustainable at the current sales base.
All data sourced from Research OS internal DB as of 2026-11-06. Candidates are screener outputs for research prioritization, not buy or sell recommendations. PEAD sub-index intersection: no 2+ overlaps on that dimension today.